ODT’s Most-Read Stories This Week—Jan. 21

New beginnings drove ODT website traffic again this past week.

Though the new year isn’t all that new anymore, cybervisitors still sought out stories of fresh starts: a new company, new product, and new studies.

Garnering the most page views was Scoliosis Technologies’ merger with European Technology, which will create a brand-new company called Scoli3D. This new firm’s mission is to deliver non-surgical scoliosis treatment with guaranteed results for U.S. children.

Not too far behind on page view totals was Enovis’ launch of the DynaClip Delta and DynaClip Quattro bone staples, followed by announced IDE studies from Lipogems and Hip Innovation Technology. 

The ARISE FDA investigational device exemption (IDE) study being conducted by Lipogems will examine its MicroFat autologous, intra-articular injection versus corticosteroid injection to treat knee osteoarthritis (OA). Lipogems’ ARISE IDE study will enroll patients at up to 20 U.S. sites to compare MicroFat with corticosteroid injection to treat pain and function for moderate knee OA.

Hip Innovation Technology LLC’s (HIT) trial, meanwhile, aims to determine the safety and effectiveness of the HIT Reverse Hip Replacement System in primary total hip arthroplasty. Safety will be assessed through the collection of device-related adverse events and patient quality of life metrics. Effectiveness will be evaluated using clinical, radiologic, and patient-reported outcomes.

1. Scoliosis Technologies Merges With European Technology to Form Scoli3D

2. Enovis Expands DynaClip Family With Debut of New Staples

3. Lipogems Begins ARISE IDE Study for Knee OA

4. Electrical Bone Growth Stimulators Market to Top $2B by End of Decade

5. Hip Innovation Technology Initiates FDA Approved Investigational Device Exemption Study